Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0094 | Pentostatin

Molecular Formula C11H16N4O4
Molecular Weight 268.27
Structure
State solid
Clearance * 68 mL/min/m2
Route of elimination In man, following a single dose of 4 mg/m2 of pentostatin infused over 5 minutes, approximately 90% of the dose was excreted in the urine as unchanged pentostatin and/or metabolites as measured by adenosine deaminase inhibitory activity.
Protein binding 0.04
Half life 5.7 hours (with a range between 2.6 and 16 hrs)
Absorption Not absorbed orally, crosses blood brain barrier.

L

L01XX08 Pentostatin


[L01XX] Other antineoplastic agents


[L01X] OTHER ANTINEOPLASTIC AGENTS


[L01] ANTINEOPLASTIC AGENTS


[L] Antineoplastic and immunomodulating agents

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 39 companies from 2 notifications to the ECHA C&L Inventory.


H301 (97.44%): Toxic if swallowed [Danger Acute toxicity, oral]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P264, P270, P301+P310, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

  • Hairy cell leukaemia

  • Candida infection (0.02)

  • Urogenital disorder (0.15)

  • Abdominal pain

  • Abscess

  • Anaemia

  • Arthralgia

  • Asthenia

  • Bacterial infection

  • Body temperature increased

  • Bronchitis

  • Cellulitis

  • Chills

  • Conjunctivitis

  • Cough

  • Decreased appetite

  • Dermatitis

  • Diarrhoea

  • Dyspnoea

  • Fatigue

  • Foetor hepaticus

  • Gastrointestinal pain

  • Headache

  • Hepatocellular injury

  • Herpes simplex

  • Herpes zoster

  • Hyperhidrosis

  • Hypersensitivity

  • Infection

  • Leukopenia

  • Liver disorder

  • Liver function test abnormal

  • Lung disorder

  • Musculoskeletal discomfort

  • Myalgia

  • Nausea

  • Nervous system disorder

  • Neurotoxicity

  • Osteomyelitis

  • Pain

  • Pharyngitis

  • Pneumonia

  • Pruritus

  • Rash

  • Rhinitis

  • Sepsis

  • Sinusitis

  • Skin disorder

  • Stomatitis

  • Thrombocytopenia

  • Upper respiratory tract infection

  • Viral infection

  • Vomiting

    • (8R)-3-(2-Deoxy-?-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,4H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol
    (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,6H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-8-ol (R)-2'-Deoxycoformycin
    (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol (R)-3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol (R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
    (R)-Deoxycoformycin (R,Z)-3-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol 2'-DCF
    2'-Deoxycoformycin 2'-Dexoycoformycin 395575MZO7
    53910-25-1 8R-2'-Deoxycoformycin 910P251
    A3708 AB0010579 AKOS024456918
    AKOS032949742 API0005275 BDBM223291
    BDBM22925 BIDD:GT0136 BRN 1223097
    C02267 CAS-53910-25-1 CHEMBL1580
    CI-825 CL 67310465 CL-67310465
    CO-Vidarabine CS-0374 Co-V
    Covidarabine D00155 DB00552
    DSSTox_CID_3436 DSSTox_GSID_23436 DSSTox_RID_77027
    DTXSID2023436 Deaminase inhibitor (PD) Deaminase, inhibitor for adenosine arabinoside
    Deoxycoformycin EN300-222177 FPVKHBSQESCIEP-JQCXWYLXSA-N
    GTPL4805 HSDB 6547 HY-A0006
    Imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)- Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- J-523899
    NCGC00182045-01 NCGC00388420-02 NSC 218321
    NSC-218321 Nipent PB12063
    PD 81565 PD-81565 PD-ADI
    Pentostatin (JAN/USAN/INN) Pentostatin (PTN) Pentostatin [USAN:INN:BAN:JAN]
    Pentostatin(Deoxycoformycin) Pentostatin, >=95% (HPLC) Pentostatina
    Pentostatina [INN-Spanish] Pentostatine Pentostatine [INN-French]
    Pentostatinum Pentostatinum [INN-Latin] Pentostatn
    Q-4464 Q425470 SCHEMBL2817
    SR-01000883935 SR-01000883935-1 Tox21_113417
    UNII-395575MZO7 Vidarbine Vira A deaminase inhibitor
    YK-176 Z2216208604 ZINC3806262
    dCF pentostatin

    DrugBank Name Pentostatin
    DrugBank DB00552
    CAS Number 53910-25-1
    PubChem Compound 439693
    KEGG Compound ID C02267
    KEGG Drug D00155
    PubChem.Substance 46507116
    PharmGKB PA450863
    ChemSpider 388759
    BindingDB 22925.0
    TTD DAP000566
    Wikipedia Pentostatin
    HET DCF
    DPD 1740

    1. Dykens et al. (2007)